Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022
The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-l...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2022-09, Vol.40 (41), p.5843-5855 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5855 |
|---|---|
| container_issue | 41 |
| container_start_page | 5843 |
| container_title | Vaccine |
| container_volume | 40 |
| creator | Prudden, Holly J. Achilles, Sharon L. Schocken, Celina Broutet, Nathalie Canfell, Karen Akaba, Hiroki Basu, Partha Bhatla, Neerja Chirenje, Z. Mike Delany-Moretlwe, Sinead Denny, Lynette Gamage, Deepa G. Herrero, Rolando Hutubessy, Raymond Villa, Luisa Lina Murillo, Raul Schiller, John T. Stanley, Margaret Temmerman, Marleen Zhao, Fanghui Ogilvie, Gina Kaslow, David C. Dull, Peter Gottlieb, Sami L |
| description | The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness. |
| doi_str_mv | 10.1016/j.vaccine.2022.08.020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2718326632</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X22009999</els_id><sourcerecordid>2715235783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-8901bd76c7c9a00797f3e27c6d965d63eab12455bfe35c2700692c8980136a4f3</originalsourceid><addsrcrecordid>eNqNUsGO0zAQjRBIlMInIFniskg0jO3ESbggtAKKtKgcWOBmufZk6yq1s7ZTCU58BJ_FV_AlOLQnLnCaGfnNG783UxSPKZQUqHi-L49Ka-uwZMBYCW0JDO4UC9o2fMVq2t4tFsBEtaoofLlfPIhxDwA1p92i-HntDIaYlDPW3ZC0QzJO28FqskM1pB05qmFCkp-Jwd66GTQG7DEENDnzZtKJ6J0KSicMNiarI-l9mKmCGnFKM9d0UI6MarTD4A_qaMMUycX6w6en5Pz1-IJ89mEwZH0auwk3ytlvKlnviPYuTkP6U8RnZKOT32IgWS399f3HexX0bi7Yw-Jer4aIj85xWVy_ef3xcr262rx9d_nqaqWrGtKq7YBuTSN0ozsF0HRNz5E1WphO1EZwVFvKqrre9shrzRoA0THddi1QLlTV82VxceLN-m8njEkebNQ4DMqhn6JkDW05E4Kz_4BCI2hV5XUsiyd_Qfd-Ci4LmQlrxuum5RlVn1A6-BjzJuQY7EGFr5KCnM9B7uXZUzl7IqGV-Rxy38tTH2ZjjhaDjNqi02hsQJ2k8fYfDL8B9BXD6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2715235783</pqid></control><display><type>article</type><title>Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022</title><source>Elsevier ScienceDirect Journals</source><creator>Prudden, Holly J. ; Achilles, Sharon L. ; Schocken, Celina ; Broutet, Nathalie ; Canfell, Karen ; Akaba, Hiroki ; Basu, Partha ; Bhatla, Neerja ; Chirenje, Z. Mike ; Delany-Moretlwe, Sinead ; Denny, Lynette ; Gamage, Deepa G. ; Herrero, Rolando ; Hutubessy, Raymond ; Villa, Luisa Lina ; Murillo, Raul ; Schiller, John T. ; Stanley, Margaret ; Temmerman, Marleen ; Zhao, Fanghui ; Ogilvie, Gina ; Kaslow, David C. ; Dull, Peter ; Gottlieb, Sami L</creator><creatorcontrib>Prudden, Holly J. ; Achilles, Sharon L. ; Schocken, Celina ; Broutet, Nathalie ; Canfell, Karen ; Akaba, Hiroki ; Basu, Partha ; Bhatla, Neerja ; Chirenje, Z. Mike ; Delany-Moretlwe, Sinead ; Denny, Lynette ; Gamage, Deepa G. ; Herrero, Rolando ; Hutubessy, Raymond ; Villa, Luisa Lina ; Murillo, Raul ; Schiller, John T. ; Stanley, Margaret ; Temmerman, Marleen ; Zhao, Fanghui ; Ogilvie, Gina ; Kaslow, David C. ; Dull, Peter ; Gottlieb, Sami L ; Therapeutic HPV Vaccine PPC Expert Consultation Group</creatorcontrib><description>The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2022.08.020</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adolescents ; Age ; Cancer ; Cancer screening ; Cervical cancer ; Cervix ; Charities ; cost effectiveness ; Genomes ; Girls ; HPV ; Human papillomavirus ; humans ; Impact prediction ; Infections ; Invasiveness ; Lesions ; Papillomaviridae ; Preferred product characteristics ; Prevention ; Public health ; Screening ; Strategy ; Therapeutic HPV vaccine ; therapeutics ; uterine cervical neoplasms ; Vaccines ; Womens health ; World Health Organization</subject><ispartof>Vaccine, 2022-09, Vol.40 (41), p.5843-5855</ispartof><rights>2022</rights><rights>Copyright Elsevier Limited Sep 29, 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-8901bd76c7c9a00797f3e27c6d965d63eab12455bfe35c2700692c8980136a4f3</citedby><cites>FETCH-LOGICAL-c450t-8901bd76c7c9a00797f3e27c6d965d63eab12455bfe35c2700692c8980136a4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X22009999$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Prudden, Holly J.</creatorcontrib><creatorcontrib>Achilles, Sharon L.</creatorcontrib><creatorcontrib>Schocken, Celina</creatorcontrib><creatorcontrib>Broutet, Nathalie</creatorcontrib><creatorcontrib>Canfell, Karen</creatorcontrib><creatorcontrib>Akaba, Hiroki</creatorcontrib><creatorcontrib>Basu, Partha</creatorcontrib><creatorcontrib>Bhatla, Neerja</creatorcontrib><creatorcontrib>Chirenje, Z. Mike</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Denny, Lynette</creatorcontrib><creatorcontrib>Gamage, Deepa G.</creatorcontrib><creatorcontrib>Herrero, Rolando</creatorcontrib><creatorcontrib>Hutubessy, Raymond</creatorcontrib><creatorcontrib>Villa, Luisa Lina</creatorcontrib><creatorcontrib>Murillo, Raul</creatorcontrib><creatorcontrib>Schiller, John T.</creatorcontrib><creatorcontrib>Stanley, Margaret</creatorcontrib><creatorcontrib>Temmerman, Marleen</creatorcontrib><creatorcontrib>Zhao, Fanghui</creatorcontrib><creatorcontrib>Ogilvie, Gina</creatorcontrib><creatorcontrib>Kaslow, David C.</creatorcontrib><creatorcontrib>Dull, Peter</creatorcontrib><creatorcontrib>Gottlieb, Sami L</creatorcontrib><creatorcontrib>Therapeutic HPV Vaccine PPC Expert Consultation Group</creatorcontrib><title>Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022</title><title>Vaccine</title><description>The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness.</description><subject>Adolescents</subject><subject>Age</subject><subject>Cancer</subject><subject>Cancer screening</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Charities</subject><subject>cost effectiveness</subject><subject>Genomes</subject><subject>Girls</subject><subject>HPV</subject><subject>Human papillomavirus</subject><subject>humans</subject><subject>Impact prediction</subject><subject>Infections</subject><subject>Invasiveness</subject><subject>Lesions</subject><subject>Papillomaviridae</subject><subject>Preferred product characteristics</subject><subject>Prevention</subject><subject>Public health</subject><subject>Screening</subject><subject>Strategy</subject><subject>Therapeutic HPV vaccine</subject><subject>therapeutics</subject><subject>uterine cervical neoplasms</subject><subject>Vaccines</subject><subject>Womens health</subject><subject>World Health Organization</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNUsGO0zAQjRBIlMInIFniskg0jO3ESbggtAKKtKgcWOBmufZk6yq1s7ZTCU58BJ_FV_AlOLQnLnCaGfnNG783UxSPKZQUqHi-L49Ka-uwZMBYCW0JDO4UC9o2fMVq2t4tFsBEtaoofLlfPIhxDwA1p92i-HntDIaYlDPW3ZC0QzJO28FqskM1pB05qmFCkp-Jwd66GTQG7DEENDnzZtKJ6J0KSicMNiarI-l9mKmCGnFKM9d0UI6MarTD4A_qaMMUycX6w6en5Pz1-IJ89mEwZH0auwk3ytlvKlnviPYuTkP6U8RnZKOT32IgWS399f3HexX0bi7Yw-Jer4aIj85xWVy_ef3xcr262rx9d_nqaqWrGtKq7YBuTSN0ozsF0HRNz5E1WphO1EZwVFvKqrre9shrzRoA0THddi1QLlTV82VxceLN-m8njEkebNQ4DMqhn6JkDW05E4Kz_4BCI2hV5XUsiyd_Qfd-Ci4LmQlrxuum5RlVn1A6-BjzJuQY7EGFr5KCnM9B7uXZUzl7IqGV-Rxy38tTH2ZjjhaDjNqi02hsQJ2k8fYfDL8B9BXD6g</recordid><startdate>20220929</startdate><enddate>20220929</enddate><creator>Prudden, Holly J.</creator><creator>Achilles, Sharon L.</creator><creator>Schocken, Celina</creator><creator>Broutet, Nathalie</creator><creator>Canfell, Karen</creator><creator>Akaba, Hiroki</creator><creator>Basu, Partha</creator><creator>Bhatla, Neerja</creator><creator>Chirenje, Z. Mike</creator><creator>Delany-Moretlwe, Sinead</creator><creator>Denny, Lynette</creator><creator>Gamage, Deepa G.</creator><creator>Herrero, Rolando</creator><creator>Hutubessy, Raymond</creator><creator>Villa, Luisa Lina</creator><creator>Murillo, Raul</creator><creator>Schiller, John T.</creator><creator>Stanley, Margaret</creator><creator>Temmerman, Marleen</creator><creator>Zhao, Fanghui</creator><creator>Ogilvie, Gina</creator><creator>Kaslow, David C.</creator><creator>Dull, Peter</creator><creator>Gottlieb, Sami L</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope></search><sort><creationdate>20220929</creationdate><title>Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022</title><author>Prudden, Holly J. ; Achilles, Sharon L. ; Schocken, Celina ; Broutet, Nathalie ; Canfell, Karen ; Akaba, Hiroki ; Basu, Partha ; Bhatla, Neerja ; Chirenje, Z. Mike ; Delany-Moretlwe, Sinead ; Denny, Lynette ; Gamage, Deepa G. ; Herrero, Rolando ; Hutubessy, Raymond ; Villa, Luisa Lina ; Murillo, Raul ; Schiller, John T. ; Stanley, Margaret ; Temmerman, Marleen ; Zhao, Fanghui ; Ogilvie, Gina ; Kaslow, David C. ; Dull, Peter ; Gottlieb, Sami L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-8901bd76c7c9a00797f3e27c6d965d63eab12455bfe35c2700692c8980136a4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adolescents</topic><topic>Age</topic><topic>Cancer</topic><topic>Cancer screening</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Charities</topic><topic>cost effectiveness</topic><topic>Genomes</topic><topic>Girls</topic><topic>HPV</topic><topic>Human papillomavirus</topic><topic>humans</topic><topic>Impact prediction</topic><topic>Infections</topic><topic>Invasiveness</topic><topic>Lesions</topic><topic>Papillomaviridae</topic><topic>Preferred product characteristics</topic><topic>Prevention</topic><topic>Public health</topic><topic>Screening</topic><topic>Strategy</topic><topic>Therapeutic HPV vaccine</topic><topic>therapeutics</topic><topic>uterine cervical neoplasms</topic><topic>Vaccines</topic><topic>Womens health</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prudden, Holly J.</creatorcontrib><creatorcontrib>Achilles, Sharon L.</creatorcontrib><creatorcontrib>Schocken, Celina</creatorcontrib><creatorcontrib>Broutet, Nathalie</creatorcontrib><creatorcontrib>Canfell, Karen</creatorcontrib><creatorcontrib>Akaba, Hiroki</creatorcontrib><creatorcontrib>Basu, Partha</creatorcontrib><creatorcontrib>Bhatla, Neerja</creatorcontrib><creatorcontrib>Chirenje, Z. Mike</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Denny, Lynette</creatorcontrib><creatorcontrib>Gamage, Deepa G.</creatorcontrib><creatorcontrib>Herrero, Rolando</creatorcontrib><creatorcontrib>Hutubessy, Raymond</creatorcontrib><creatorcontrib>Villa, Luisa Lina</creatorcontrib><creatorcontrib>Murillo, Raul</creatorcontrib><creatorcontrib>Schiller, John T.</creatorcontrib><creatorcontrib>Stanley, Margaret</creatorcontrib><creatorcontrib>Temmerman, Marleen</creatorcontrib><creatorcontrib>Zhao, Fanghui</creatorcontrib><creatorcontrib>Ogilvie, Gina</creatorcontrib><creatorcontrib>Kaslow, David C.</creatorcontrib><creatorcontrib>Dull, Peter</creatorcontrib><creatorcontrib>Gottlieb, Sami L</creatorcontrib><creatorcontrib>Therapeutic HPV Vaccine PPC Expert Consultation Group</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prudden, Holly J.</au><au>Achilles, Sharon L.</au><au>Schocken, Celina</au><au>Broutet, Nathalie</au><au>Canfell, Karen</au><au>Akaba, Hiroki</au><au>Basu, Partha</au><au>Bhatla, Neerja</au><au>Chirenje, Z. Mike</au><au>Delany-Moretlwe, Sinead</au><au>Denny, Lynette</au><au>Gamage, Deepa G.</au><au>Herrero, Rolando</au><au>Hutubessy, Raymond</au><au>Villa, Luisa Lina</au><au>Murillo, Raul</au><au>Schiller, John T.</au><au>Stanley, Margaret</au><au>Temmerman, Marleen</au><au>Zhao, Fanghui</au><au>Ogilvie, Gina</au><au>Kaslow, David C.</au><au>Dull, Peter</au><au>Gottlieb, Sami L</au><aucorp>Therapeutic HPV Vaccine PPC Expert Consultation Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022</atitle><jtitle>Vaccine</jtitle><date>2022-09-29</date><risdate>2022</risdate><volume>40</volume><issue>41</issue><spage>5843</spage><epage>5855</epage><pages>5843-5855</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>The World Health Organization (WHO) global strategy to eliminate cervical cancer (CxCa) could result in >62 million lives saved by 2120 if strategy targets are reached and maintained: 90% of adolescent girls receiving prophylactic human papillomavirus (HPV) vaccine, 70% of women receiving twice-lifetime cervical cancer screening, and 90% of cervical pre-cancer lesions and invasive CxCa treated. However, the cost and complexity of CxCa screening and treatment approaches has hampered scale-up, particularly in low- and middle-income countries (LMICs), and new approaches are needed. Therapeutic HPV vaccines (TxV), which could clear persistent high-risk HPV infection and/or cause regression of pre-cancerous lesions, are in early clinical development and might offer one such approach. During October 2021 to March 2022, WHO, in collaboration with the Bill and Melinda Gates Foundation, convened a series of global expert consultations to lay the groundwork for understanding the potential value of TxV in the context of current CxCa prevention efforts and for defining WHO preferred product characteristics (PPCs) for TxV. WHO PPCs describe preferences for vaccine attributes that would help optimize vaccine value and use in meeting the global public health need. This paper reports on the main discussion points and findings from the expert consultations. Experts identified several ways in which TxV might address challenges in current CxCa prevention programmes, but emphasized that the potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions. Consultation participants also discussed potential use-cases for TxV, important PPC considerations (e.g., vaccine indications, target populations, and delivery strategies), and critical modelling needs for predicting TxV impact and cost-effectiveness.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.vaccine.2022.08.020</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2022-09, Vol.40 (41), p.5843-5855 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2718326632 |
| source | Elsevier ScienceDirect Journals |
| subjects | Adolescents Age Cancer Cancer screening Cervical cancer Cervix Charities cost effectiveness Genomes Girls HPV Human papillomavirus humans Impact prediction Infections Invasiveness Lesions Papillomaviridae Preferred product characteristics Prevention Public health Screening Strategy Therapeutic HPV vaccine therapeutics uterine cervical neoplasms Vaccines Womens health World Health Organization |
| title | Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021—March 2022 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A19%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20the%20public%20health%20value%20and%20defining%20preferred%20product%20characteristics%20for%20therapeutic%20human%20papillomavirus%20(HPV)%20vaccines:%20World%20Health%20Organization%20consultations,%20October%202021%E2%80%94March%202022&rft.jtitle=Vaccine&rft.au=Prudden,%20Holly%20J.&rft.aucorp=Therapeutic%20HPV%20Vaccine%20PPC%20Expert%20Consultation%20Group&rft.date=2022-09-29&rft.volume=40&rft.issue=41&rft.spage=5843&rft.epage=5855&rft.pages=5843-5855&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2022.08.020&rft_dat=%3Cproquest_cross%3E2715235783%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2715235783&rft_id=info:pmid/&rft_els_id=S0264410X22009999&rfr_iscdi=true |